WO2012046238A2 - Antagonistes du récepteur d'érythropoïétine - Google Patents

Antagonistes du récepteur d'érythropoïétine Download PDF

Info

Publication number
WO2012046238A2
WO2012046238A2 PCT/IL2011/000788 IL2011000788W WO2012046238A2 WO 2012046238 A2 WO2012046238 A2 WO 2012046238A2 IL 2011000788 W IL2011000788 W IL 2011000788W WO 2012046238 A2 WO2012046238 A2 WO 2012046238A2
Authority
WO
WIPO (PCT)
Prior art keywords
epo
peptide
group
amino acid
leu
Prior art date
Application number
PCT/IL2011/000788
Other languages
English (en)
Other versions
WO2012046238A3 (fr
Inventor
Tamar Liron
Miriam Souroujon
Drorit Neumann
Original Assignee
Ramot At Tel-Aviv University Ltd.
Opmop Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel-Aviv University Ltd., Opmop Ltd. filed Critical Ramot At Tel-Aviv University Ltd.
Publication of WO2012046238A2 publication Critical patent/WO2012046238A2/fr
Publication of WO2012046238A3 publication Critical patent/WO2012046238A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids

Abstract

La présente invention concerne des peptides dérivés de l'érythropoïétine qui se lient au récepteur de l'érythropoïétine et inhibent la prolifération des cellules induite par l'EPO. L'invention concerne en plus des compositions pharmaceutiques les comprenant, et les utilisations de ceux-ci dans le traitement de l'érythrocytose primaire et secondaire ainsi que pour l'inhibition de la prolifération des cellules indésirables induite par le récepteur de l'érythropoïétine chez des patients traités avec l'érythropoïétine.
PCT/IL2011/000788 2010-10-06 2011-10-06 Antagonistes du récepteur d'érythropoïétine WO2012046238A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39025310P 2010-10-06 2010-10-06
US61/390,253 2010-10-06

Publications (2)

Publication Number Publication Date
WO2012046238A2 true WO2012046238A2 (fr) 2012-04-12
WO2012046238A3 WO2012046238A3 (fr) 2012-08-09

Family

ID=44971068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2011/000788 WO2012046238A2 (fr) 2010-10-06 2011-10-06 Antagonistes du récepteur d'érythropoïétine

Country Status (1)

Country Link
WO (1) WO2012046238A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264166A1 (fr) 1986-04-09 1988-04-20 Genzyme Corporation Animaux transformés génétiquement sécrétant une protéine désirée dans le lait
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5932447A (en) 1994-05-17 1999-08-03 Bristol-Myers Squibb Company Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO2004003176A2 (fr) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
JP2006512300A (ja) * 2002-10-03 2006-04-13 エピミューン インコーポレイテッド Ｈｌａ結合ペプチド及びその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264166A1 (fr) 1986-04-09 1988-04-20 Genzyme Corporation Animaux transformés génétiquement sécrétant une protéine désirée dans le lait
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5487992A (en) 1989-08-22 1996-01-30 University Of Utah Research Foundation Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
US5932447A (en) 1994-05-17 1999-08-03 Bristol-Myers Squibb Company Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", MACK PUBLISHING CO.
"Vectors: A Survey of Molecular Cloning Vectors and Their Uses", 1988, BUTTERWORTHS
ARCASOY M. 0., BR. J. HAEMATOL, vol. 141, 2008, pages 14 - 31
ARCASOY, M. O. ET AL., EXP. HEMATOL., vol. 27, 1999, pages 63 - 74
AUSUBEL ET AL.,: "Current Protocols in Molecular Biology", 1992, JOHN WILEY & SONS
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1989, JOHN WILEY AND SONS
BANERJI ET AL., CELL, 1983, pages 33729 - 740
BARBONE F. P. ET AL., J BIOL. CHEM., vol. 272, 1997, pages 4985 - 92
BITTER ET AL., METHODS IN ENZYMOL., vol. 153, 1987, pages 516 - 544
BOOTH ET AL., IMMUNOL. LETT., vol. 19, 1988, pages 65 - 70
BRISSON ET AL., NATURE, vol. 310, 1984, pages 511 - 514
BROGLI ET AL., SCIENCE, vol. 224, 1984, pages 838 - 843
BYRNE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 5473 - 5477
CALAME ET AL., ADV. IMMUNOL., vol. 43, 1988, pages 235 - 275
CHANG ET AL.: "Somatic Gene Therapy", 1995, CRC PRESS
CHEN, J. ET AL., EXP. CELL RES., vol. 298, 2004, pages 155 - 66
COHEN, J. ET AL., BIOCHEM J, vol. 327, 1997, pages 391 - 7
CORUZZI ET AL., EMBO J., vol. 3, 1984, pages 1671 - 1680
CREIGHTON T.: "Proteins, structures and molecular principles", 1983, WH FREEMAN AND CO.
EDLUNCH ET AL., SCIENCE, vol. 230, 1985, pages 912 - 916
ELLIOTT S. ET AL., BLOOD, vol. 89, 1997, pages 493 - 502
FANDREY, J. ET AL., ONCOLOGIST, vol. 14, 2009, pages 34 - 42
GARDELLA ET AL., J. BIOL. CHEM., vol. 265, 1990, pages 15854 - 15859
GENNARO, A.: "Remington: The Science and Practice of Pharmacy, 20th ed,", 2000, LIPPINCOTT, WILLIAMS & WILKINS
GILBOA, BIOTECHNIQUES, vol. 4, no. 6, 1986, pages 504 - 512
GORDEUK, V. R. ET AL., HAEMATOLOGICA, vol. 90, 2005, pages 109 - 16
GURLEY ET AL., MOL. CELL. BIOL., vol. 6, 1986, pages 559 - 565
HEDLEY BD ET AL., CLIN CANCER RES, vol. 17, no. 19, 2011, pages 1 - 12
JOHN MORROW STEWART; JANIS DILLAHA YOUNG: "Solid Phase Polypeptide Syntheses(2nd Ed.,", 1984, PIERCE CHEMICAL COMPANY
JORDAN, M. ET AL., NUCLEIC ACIDS RES, vol. 24, 1996, pages 596 - 601
LIVNAH O. ET AL., SCIENCE, vol. 273, 1996, pages 464 - 7
MCMULLIN M. F., INT. J LAB. HEMATOL., vol. 30, 2008, pages 447 - 59
NALBANT D ET AL., J PHARMACOL EXP THER, vol. 333, 2010, pages 528 - 32
PATNAIK M. M.; TEFFERI A., LEUKEMIA, vol. 23, 2009, pages 834 - 44
PINKERT ET AL., GENES DEV., vol. 1, 1987, pages 268 - 277
RAVID, O. ET AL., PROC NATL ACAD SCI U S A, vol. 104, 2007, pages 14360 - 5
RICHMOND, T. D. ET AL., TRENDS CELL BIOL, vol. 15, 2005, pages 146 - 55
RICHMOND, T. D. ET AL., TRENDS CELL BIOL., vol. 15, 2005, pages 146 - 55
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRINGS HARBOR LABORATORY
SASAKI ET AL., BIOSCI. BIOTECHNOL. BIOCHEM., vol. 64, 2000, pages 1775 - 93
SHI Z ET AL., MOL CANCER RES, vol. 8, 2010, pages 615 - 626
SROUR, M.A. ET AL., THROMB. HAEMOST., vol. 90, 2003, pages 398 - 405
STUDIER ET AL., METHODS IN ENZYMOL., vol. 185, 1990, pages 60 - 89
SYED R. S. ET AL., NATURE, vol. 395, 1998, pages 511 - 6
SYED, R. S. ET AL., NATURE, vol. 395, 1998, pages 511 - 6
TAKAMATSU ET AL., EMBO J., vol. 6, 1987, pages 307 - 311
VAN MAERKEN, T. ET AL., J. PEDIATR. HEMATOL. ONCOL., vol. 26, 2004, pages 407 - 16
VEGA ET AL.: "Gene Targeting", 1995, CRC PRESS
WEISSBACH; WEISSBACH: "Methods for Plant Molecular Biology", 1988, ACADEMIC PRESS, pages: 421 - 463
WINOTO ET AL., EMBO J., vol. 8, 1989, pages 729 - 733
WOJCHOWSKI, D.M. ET AL., EXP. CELL RES., vol. 253, 1999, pages 143 - 56
YOUSSOUFIAN, H. ET AL., BLOOD, vol. 81, 1993, pages 2223 - 36
ZHAO, W. ET AL., BLOOD, vol. 107, 2006, pages 907 - 15

Also Published As

Publication number Publication date
WO2012046238A3 (fr) 2012-08-09

Similar Documents

Publication Publication Date Title
CN101123978B (zh) 神经胚素变体
KR101626153B1 (ko) 조직 보호 펩티드 및 이의 용도
CA2658231C (fr) Methode de production de proteines tat-hoxb4h recombinantes pouvant servir, in vivo, de stimulateurs de l'hematopoiese
CN104211800A (zh) 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体
CN105837680A (zh) 治疗fgf21相关的病症的方法
TW201919685A (zh) 使用ｇｄｆ阱以增加紅血球水平
CN102924585A (zh) 神经胚素变体
US20090018060A1 (en) Thymus-specific protein
EA001204B1 (ru) Усеченный нейротрофический фактор глиальной клеточной линии, днк, кодирующая указанный фактор, вектор, содержащий указанную днк, способ получения фактора, фармацевтическая композиция и способ лечения
JPH07506488A (ja) ｎｅｕレセプターの組換え刺激因子
KR20200128091A (ko) 성장분화인자 15 효능제 화합물 및 이를 사용하는 방법
US20090221506A1 (en) Gdnf derived peptides
CN107022032A (zh) 用于调节铁稳态的组合物及其使用方法
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
PT1355936E (pt) Conjugados poliméricos de neublastina e métodos para a sua utilização
JPWO2007072980A1 (ja) アペリンの新規用途
WO2012046238A2 (fr) Antagonistes du récepteur d'érythropoïétine
US20220135971A1 (en) Core master regulators of glioblastoma stem cells
CA2870769C (fr) Antagonistes de facteur de croissance endothelial vasculaire et methodes destinees a leur utilisation
TWI748306B (zh) 包含人類Lefty A蛋白變體的融合蛋白及其用途
CN113018418B (zh) 微小RNA31前体编码多肽miPEP31在制备高血压药物中的应用
KR20130126549A (ko) 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
CA3223071A1 (fr) Nouveau mutant de proteine immunoregulatrice de ganoderma lucidum recombinante et son application
WO2016086960A1 (fr) Propriétés anti-angiogéniques de fragments dérivés de collagène v
CN112368377A (zh) 用于治疗重症联合免疫缺陷的包含细胞穿透肽和腺苷脱氨酶的融合蛋白的药物组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11782480

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11782480

Country of ref document: EP

Kind code of ref document: A2